We found that clinicopathological and imaging characteristics of lesions in patients with sMPLA could assist to predict the mutation status of EGFR, TP53 and KRAS, and provide direction for precise treatment strategies for synchronous multiple primary lung adenocarcinoma. The gene discussed is TP53; the disease is lung adenocarcinoma.